May 21, 2009 — In patients with follicular lymphoma, rituximab (Rituxan, Genentech; MabThera, Roche) maintenance therapy significantly improves overall survival, compared with observation or ...

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

Patients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this ...

Patients with follicular lymphoma, a slow-growing common type of non-Hodgkin's lymphoma, who are given 2 years of rituximab-maintenance therapy after immunochemotherapy, have significantly better ...

At close to 15 years, 65% of patients on rituximab maintenance required no further treatment. ... Considering the median age at diagnosis is over 65 in follicular lymphoma, ...

In follicular lymphoma (FL), the chimeric anti-CD20 monoclonal antibody rituximab has improved response rates, progression-free survival (PFS), and overall survival (OS) to such an extent that the ...

ATLANTA -- Patients with newly diagnosed low-burden follicular lymphoma (FL) in remission avoided chemotherapy significantly longer if they received maintenance rituximab (Rituxan) instead of ...

Obinutuzumab-based chemoimmunotherapy and maintenance therapy conferred longer PFS than rituximab-based therapy for the first-line treatment of follicular lymphoma, according to the randomized ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of rituximab maintenance treatment for people with follicular non-Hodgkin's lymphoma that has responded to ...

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low tumor burden follicular lymphoma can substantially delay the need for ...